Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension study of pelacarsen long-term safety and tolerability after Lp(a)HORIZON
CTR20253059Phase 3Active
- Sponsor
- Novartis
- Start
- May 2026
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of pelacarsen in cardiac morbidity, lipoprotein(a) hyperlipoproteinemia (Lp(a)), sponsored by Novartis. Started May 2026; status: active.
02
Drugs
pelacarsen
03
Conditions
cardiac morbiditylipoprotein(a) hyperlipoproteinemia (Lp(a))
Beyond the preview
Go deeper on CTR20253059.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20253059.